DAFTAR PUSTAKA

Abdou, H. M. (1989), Dissolution, Bioavailability & Bioequivalence, Mack Publishing, Easton, Pesnylvania. 481.

Achimastos, A., Liberopoulos, E., Nikas, S., Bairaktari, E., Miltiadous, G., Tsimihodimos, V., & Elisaf, M. (2002). The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. *Current Medical Research and Opinion*, *18*(2), 59–63.

Ainurofiq, A., Mauludin, R., Mudhakir, D., & Soewandhi, S. (2018). Synthesis, characterization, and stability study of desloratadine multicomponent crystal formation. Research in Pharmaceutical Sciences, 13(2), 93–102.

Alagona, P. (2010). Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. *Vascular Health and Risk Management*, *6*(1), 351–362.

Alatas, F., Soewandhi, S. N., & Sasongko, L. (2014). Kelarutan Dan Stabilitas Kimia Kompleks Didanosin Dengan Nikotinamid Atau L-Arginin. *Jurnal Sains Materi Indonesia*, *15*(2), 94–102.

Alatas, F., Soewandhi, S. N., Sasongko, L., Ismunandar, & Uekusa, H. (2013). Cocrystal formation between didanosine and two aromatic acids. International Journal of Pharmacy and Pharmaceutical Sciences, 5(SUPPL 3), 275–280.

Ahuja, S. & Rasmussen, H., (2007), HPLC Method Development for Pharmaceuticals, Elsevier, Academic Press, 111-144.

Anief, M., (2006), Ilmu Meracik Obat, Gadjah Mada University Press, Yogyakarta

Ansel, H. C., (1989), Pengantar Bentuk Sediaan Farmasi, diterjemahkan oleh Ibrahim, F., Edisi keempat, 607-608, Jakarta, Universitas Indonesia Press.

Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J. C., Glineur, C., & Staels, B. (2002). Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *22*(5), 717–726.

Bazzo, G. C., Pezzini, B. R., & Stulzer, H. K. (2020). Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. International Journal of Pharmaceutics, 588, 119741.

Burke, R. W.. (1974) "Mechanisms of the Liebermann Burchard and Zak color reactions for cholesterol," *Clinical Chemistry*, 20(7), hal. 794–801.

Berry, D. J., Seaton, C. C., Clegg, W., Harrington, R. W., Coles, S. J., Horton, P. N., Hursthouse, M. B., Storey, R., Jones, W., Friščić, T., & Blagden, N. (2008).

Applying hot-stage microscopy to co-crystal screening: A study of nicotinamide with seven active pharmaceutical ingredients. Crystal Growth and Design, 8(5), 1697–1712.

Blesso, C. N., & Fernandez, M. L. (2018). Dietary cholesterol, serum lipids, and heart disease: Are eggs working for or against you? Nutrients, 10(4). https://doi.org/10.3390/nu10040426

Cayman Chemical (2017) "Product Information. Fenofibric Acid," *Cayman Chemical Company*.

Chadha, K., Karan, M., Chadha, R., Bhalla, Y., & Vasisht, K. (2017). Is Failure of Cocrystallization Actually a Failure? Eutectic Formation in Cocrystal Screening of Hesperetin. Journal of Pharmaceutical Sciences, 106(8), 2026–2036.

Chapman, M. J. (1987). Pharmacology of fenofibrate. *The American Journal of Medicine*, *83*(5 SUPPL. 2), 21–25.

Cherukuvada, S., & Nangia, A. (2012). Fast dissolving eutectic compositions of two anti-tubercular drugs. CrystEngComm, 14(7), 2579–2588.

Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., MinNICh, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J. C., Clavey, V., & Staels, B. (2001). PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nature Medicine*, *7*(1), 53–58.

Childs, S. L., Stahly, G. P., & Park, A. (2007). The salt-cocrystal continuum: The influence of crystal structure on ionization state. Molecular Pharmaceutics, 4(3), 323–338.

Cooper, A., Nutley, M. a., & Wadood, A. (2000). *Protein-Ligand Interactions: hydrodynamics and calorimetry-Differential scanning microcalorimetry*. 287–318.

Dwichandra Putra, O., Yonemochi, E., & Uekusa, H. (2016). Isostructural Multicomponent Gliclazide Crystals with Improved Solubility. *Crystal Growth and Design*, *16*(11), 6568–6573.

Dalal, N., Buckner, I. S., & Wildfong, P. L. D. (2017). Experimental Determination and Theoretical Calculation of the Eutectic Composition of Cefuroxime Axetil Diastereomers. AAPS PharmSciTech, 18(7), 2570–2578.

Dedhiya, P. P., Chauhan, R. S., Shah, S. A., & Tailor, P. M. (2014). Determination of fenofibric acid (Related substance) in marketed formulations of fenofibrate by RP-HPLC. Journal of Pharmaceutical Sciences and Research, 6(10), 313–320.

DepKes, RI. (2014). Farmakope Indonesia (5Th Ed). In Jakarta.

Douroumis, D., & Fahr, A. (2013). Drug Delivery Strategies for Poorly Water-Soluble Drugs. *Drug Delivery Strategies for Poorly Water-Soluble Drugs*, 1481–1500.

Duggirala, N. K., Perry, M. L., Almarsson, Ö., & Zaworotko, M. J. (2016). Pharmaceutical cocrystals: Along the path to improved medicines. Chemical Communications, 52(4), 640–655.

Fernandes, G. J., Kumar, L., Sharma, K., Tunge, R., & Rathnanand, M. (2018). A Review on Solubility Enhancement of Carvedilol—a BCS Class II Drug. *Journal of Pharmaceutical Innovation*, *13*(3), 197–212.

Ferreira, P. O., de Almeida, A. C., dos Santos, É. C., Droppa, R., Ferreira, F. F., Kogawa, A. C., & Caires, F. J. (2020). A norfloxacin-Nicotinic acid cocrystal: Mechanochemical synthesis, thermal and structural characterization and solubility assays. Thermochimica Acta, 694(September).

Fudholi A., 2013, Disolusi dan Pelepasan Obat In Vitro, Penerbit Pustaka Pelajar, Yogyakarta.

Godfrey, A. R., DiGiacinto, J., & Davis, M. W. (2011). Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover CliNICal Trials. *CliNICal Therapeutics*, *33*(6), 766–775.

Górniak, A., Wojakowska, A., Karolewicz, B., & Pluta, J. (2011). Phase diagram and dissolution studies of the fenofibrate-acetylsalicylic acid system. Journal of Thermal Analysis and Calorimetry, 104(3), 1195–1200. https://doi.org/10.1007/s10973-010-1148-3

Ghosh, T., Juturu, T., Nagar, S. N., & Kamath, S. (2021). Cocrystals of Modafinil-niotinic acid: A Novel Cocrystal for Enhanced Bioavailability. Proceedings, 62(1), 12.

Grothe, E., Meekes, H., Vlieg, E., Ter Horst, J. H., & De Gelder, R. (2016). Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Crystal Growth and Design*, *16*(6), 3237–3243. Guyton, A. C., Hall, J. E., 2014. Buku Ajar Fisiologi Kedokteran. Edisi 12. Jakarta : EGC, 1022

Ganong, W. F., 2008. Buku Ajar Fisiologi Kedokteran. Edisi 22. Jakarta : EGC , 280- 81.

Gandjar, I.G., dan Rohman, A., (2013). Analisis Obat Secara Spektrofotometri dan Kromatografi. Yogyakarta : Pustaka Pelajar

Harmita, 2004, Petunjuk Pelaksanaan Validasi Metode dan Cara Perhitungannya, Review Artikel, *Majalah Ilmu Kefarmasian*, Vol. I, No.3, 117 - 135

Haneef, J., & Chadha, R. (2018). Antioxidant-Based Eutectics of Irbesartan: Viable

Multicomponent Forms for the Management of Hypertension. AAPS PharmSciTech, 19(3), 1191–1204.

Harmonised, I. C. H. dan Guideline, T. (1994) "Validation of Analytical Procedures : Text and Methodology," ICH Harmonised Tripartite Guideline

Higuchi, T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. *Journal of Pharmaceutical Sciences*, *52*(12), 1145–1149.

Indra, P., Zaini, E., Ismed, F., & Lucida, H. (2020). *Preparation and characterization of quercetin-polyvinylpyrrolidone K-30 spray dried solid dispersion*. *8*(10), 127–134.

Information, N. (2016). *Niacin 1,2*. *1*, 556–558. https://doi.org/10.3945/an.115.011239

ICH Harmonised Tripartite Guideline. (2018). Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV. ICH Harmonised Tripartite Guideline, 52(1010), 309–352.

Jayasankar, A., Somwangthanaroj, A., Shao, Z. J., & Rodríguez-Hornedo, N. (2006). Cocrystal formation during cogrinding and storage is mediated by amorphous phase. *Pharmaceutical Research*, *23*(10), 2381–2392.

Jones, P. H. (2009). Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia. *CliNICal Lipidology*, *4*(6), 699–711.

Kalepu, S., & Nekkanti, V. (2015). Insoluble drug delivery strategies: Review of recent advances and business prospects. *Acta Pharmaceutica SiNICa B*, *5*(5), 442–453.

Kamiya, Y., Takaku, H., Yamada, R., Akase, C., Abe, Y., Sekiguchi, Y., Murayama, N., Shimizu, M., Kitajima, M., Shono, F., Funatsu, K., & Yamazaki, H. (2020). Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals/drugs for estimation of oral absorption as a putative marker of hepatotoxicity. *Toxicology Reports*, *7*(October 2019), 149–154.

Karagianni, A., Malamatari, M., & Kachrimanis, K. (2018). Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. *Pharmaceutics*, *10*(1), 1–30.

Katzung, B. dan Trevor, A. (2015) "Katzung's Basic & Clinical Pharmacology," Basic and clinical Pharmacology, hal. 313–329.

Keating, G. M. (2011). Fenofibrate: A review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. *American Journal of Cardiovascular Drugs*, *11*(4), 227–247. https://doi.org/10.2165/11207690-000000000-00000

Kelly, D. P. (2001). The Pleiotropic Nature of the Vascular PPAR Gene Regulatory Pathway Daniel P. Kelly Circ Res. 2001;89:935-937. *Circulation Research*, *89*, 935–937. https://doi.org/10.1161/hh2301.101005

Kim, K. S., Kim, J. H., Jin, S. G., Kim, D. W., Kim, D. S., Kim, J. O., Yong, C. S., Cho, K. H., Li, D. X., Woo, J. S., & Choi, H. G. (2016). Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer. *Archives of Pharmacal Research*, *39*(4), 531–538. https://doi.org/10.1007/s12272-015-0701-9

Kotak, U., Prajapati, V., Solanki, H., Jani, G., & Jha, P. (2015). Co-crystallization Technique-Its rationale and recent progress. *World Journal of Pharmacy and Pharmaceutical Sciences*, *4*(04), 1484–1508.

Kumar A. 2019. Fourier transform infrared spectroscopy: Data interpretation and applications in structure elucidation and analysis of small molecules and nanostructures, Data Processing Handbook for Complex Biological Data Sources. Elsevier HS Journals. 77-96.

Lapidus, H., & Lordi, N. G. (1968). Drug release from compressed hydrophilic matrices. Journal of Pharmaceutical Sciences, 57(8), 1292–1301. https://doi.org/10.1002/jps.2600570803

Li, N., Sui, Z., Liu, Y., Wang, D., Ge, G., & Yang, L. (2018). A fast screening model for drug permeability assessment based on native small intestinal extracellular matrix. *RSC Advances*, *8*(60), 34514–34524. https://doi.org/10.1039/C8RA05992F

Ling. (2013). A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. *Cardiology Research*, *4*(2), 47–55. https://doi.org/10.4021/cr270w

Martin, A., Swarbick, J., dan A. Cammarata. 1993. Farmasi Fisik 2. Edisi III. Jakarta: UI Press. Pp. 940-1010, 1162, 1163, 1170.

Menkes RI, 2013, Peraturan Menteri Kesehatan No 87 tahun 2013 Tentang Peta Jalan Pengembangan Bahan baku Obat

Munoz, A., Guichard, J. P., & Reginault, P. (1994). Micronised fenofibrate. *Atherosclerosis*, *110*(SUPPL.), 45–48. https://doi.org/10.1016/0021-9150(94)05375

Murray, R.K., Granner, D.K., dan Rodwell, V.W., 2009. Biokimia Harper. Edisi 25. Penerbit Buku Kedokteran EGC.

Number, P., Information, P., Specification, T., Information, S., & Information, T. (1920). Product Information Product Information. *14998*, 1919–1920.

P Chavda, V. (2017). Biological Classification System (BCS); with a New Perspective.

MOJ Bioequivalence & Bioavailability, *3*(4), 108–109. https://doi.org/10.15406/mojbb.2017.03.00043

Padrela, L., De Azevedo, E. G., & Velaga, S. P. (2012). Powder X-ray diffraction method for the quantification of cocrystals in the crystallization mixture. *Drug Development and Industrial Pharmacy*, *38*(8), 923–929. https://doi.org/10.3109/03639045.2011.633263

Patole, T., & Deshpande, A. (2014). Co-Crystallization-a Technique for Solubility Enhancement. *International Journal of Pharmaceutical Sciences and Research*, *5*(9), 3566. https://doi.org/10.13040/IJPSR.0975-8232.5(9).3566-76

Pereira-da-silva, M. D. A. (2017). 1 - Scanning Electron Microscopy. 1–35.

Putra, O. D., Furuishi, T., Yonemochi, E., Terada, K., & Uekusa, H. (2016). Drug-Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs. *Crystal Growth and Design*, *16*(7), 3577–3581. https://doi.org/10.1021/acs.cgd.6b00639

Pradana, M. S. dan Suryanto, I. (2017) "Terapi Hiperkolesterol pada Mencit (Mus musculus) strain Balb/C Betina Umur 2 Bulan Menggunakan Sari Bawang Putih," *Biota*, 3(2), hal. 71. doi: 10.19109/biota.v3i2.1313.

Prousky, J., Millman, C. G., & Kirkland, J. B. (2011). Pharmacologic use of niacin. Complementary Health Practice Review, 16(2), 91–101 https://doi.org/10.1177/2156587211399579

Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011). Pharmaceutical cocrystals: An overview. *International Journal of Pharmaceutics*, *419*(1–2), 1–11. https://doi.org/10.1016/j.ijpharm.2011.07.037

Ravisankar, P. *et al.* (2015) "A Review on Step-by-Step Analytical Method Validation," *IOSR Journal Of Pharmacy*, 5(10), hal. 7–19.

Ronald, A. Sacher. (2004). Tinjauan Klinis Hasil Pemeriksaan Laboratorium. Jakarta: Gramedia Pustaka Utama.

Sabri, L & Hastono, S.P. (2018), Statistik Kesehatan; (9th Ed); Rajawali Press

Samaha, D., Shehayeb, R., & Kyriacos, S. (2009). Modeling and comparison of dissolution profiles of diltiazem modified-release formulations. Dissolution Technologies, 16(2), 41–46. https://doi.org/10.14227/DT160209P41

Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharmaceutics*, *2012*(100 mL), 1–10. https://doi.org/10.5402/2012/195727

Saha, S., & Desiraju, G. R. (2018). Acid···Amide Supramolecular Synthon in Cocrystals:

From Spectroscopic Detection to Property Engineering. Journal of the American Chemical Society, 140(20), 6361–6373. https://doi.org/10.1021/jacs.8b02435

Sekiguchi, K., Obi, N., 1961. Studies on Absorption of Eutectic Mixture. I. A Comparison of the Behavior of Eutectic Mixture of Sulfathiazole and that of Ordinary Sulfathiazole in Man. Chem. Pharm. Bull. (Tokyo). 9, 866–872. https://doi.org/10.1248/cpb.9.866

Sanphui, P., Devi, V. K., Clara, D., Malviya, N., Ganguly, S., & Desiraju, G. R. (2015). Cocrystals of hydrochlorothiazide: Solubility and diffusion/permeability enhancements through drug-coformer interactions. Molecular Pharmaceutics, 12(5), 1615–1622. https://doi.org/10.1021/acs.molpharmaceut.5b00020

Setyari, P. R., Wirasutha, I. G. dan Junitha, I. K. (2008) "Metode Analisis Kualitatif Dan Kuantitatif LDL-C (Rosi S ., Gelgel W ., Junitha) Metode Analisis Kualitatif Dan Kuantitatif LDL-C (Rosi S ., Gelgel W ., Junitha)," hal. 24–30.

Shargel, L., Yu, A., and Wu, S., 2005, Biofarmasetika dan Farmakokinetika Terapan, Edisi kedua, Airlangga University Press, Surabaya. 167 – 187.

Systems, M. (n.d.). Chapter Outline : Phase Diagrams A single-phase system is called homogeneous , systems with two or more phases are mixtures or. 1–57.

Sopyan, I., Fudholi, A., Muchtaridi, M., & Sari, I. P. (2017). Simvastatin-Nicotinamide co-crystal: Design, preparation and preliminary characterization. *Tropical Journal of Pharmaceutical Research*, *16*(2), 297–303. https://doi.org/10.4314/tjpr.v16i2.6

Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J. C. (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation*, *98*(19), 2088–2093. https://doi.org/10.1161/01.CIR.98.19.2088

Stoler, E., & Warner, J. C. (2015). Non-Covalent derivatives: Cocrystals and eutectics. Molecules, 20(8), 14833–14848. https://doi.org/10.3390/molecules200814833

Suhery, W. N., Sumirtapura, Y. C., Pamudji, J. S., & Mudhakir, D. (2020). Development and characterization of self-nanoemulsifying drug delivery system (Snedds) formulation for enhancing dissolution of fenofibric acid. *Journal of Research in Pharmacy*, *24*(5), 738–747. https://doi.org/10.35333/jrp.2020.227

Susan Marie Schima. (2011). Fenofibric Acid: Safety and Efficacy in the Treatment of Dyslipidemia, Hypertriglyceridemia and Hyperlipidemia. *CliNICal Medicine Reviews in Vascular Health*, *3*, 99–105. https://doi.org/10.4137/cmrvh.s5041

Suzuki, Y., Muangnoi, C., Thaweesest, W., Teerawonganan, P., Ratnatilaka, P., Bhuket, N., Titapiwatanakun, V., Yoshimura-fujii, M., Sritularak, B., Likhitwitayawuid, K., Rojsitthisak, P., & Fukami, T. (2019). *Exploring Novel Cocrystalline Forms of*

Oxyresveratrol to Enhance Aqueous Solubility and Permeability across a Cell Monolayer. *42*(6), 1004–1012

Tanaka, K. (1977). NII-ElectroNIC Library Service. Chemical Pharmaceutical Bulletin, 57(534), 364–370. http://www.mendeley.com/research/geology-volcaNIC-history-eruptive-style-yakedake-volcano-group-central-japan/

Tepzz, T., & Hyun, J. (2017). Tepzz 558z77b_t (11). 1(19), 1–21.

Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013). Pharmaceutical cocrystals and poorly soluble drugs. International Journal of zPharmaceutics, 453(1), 101–125. https://doi.org/10.1016/j.ijpharm.2012.10.043

Tojcic, J., Benoit-Biancamano, M. O., Court, M. H., Straka, R. J., Caron, P., & Guillemette, C. (2009). In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. *Drug Metabolism and Disposition*, *37*(11), 2236–2243. https://doi.org/10.1124/dmd.109.029058

Trask, A. V., & Jones, W. (2005). Crystal engineering of orgaNIC cocrystals by the solid-state grinding approach. Topics in Current Chemistry, 254, 41–70. https://doi.org/10.1007/b100995

Tsume, Y., Mudie, D. M., Langguth, P., Amidon, G. E., & Amidon, G. L. (2014). The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. *European Journal of Pharmaceutical Sciences*, *57*(1), 152–163. https://doi.org/10.1016/j.ejps.2014.01.009

Tziomalos, K., & Athyros, V. G. (2006). Fenofibrate: A novel formulation (Triglide^{TM}) in the treatment of lipid disorders: A review. *International Journal of Nanomedicine*, *1*(2), 129–147. https://doi.org/10.2147/nano.2006.1.2.129

Us, I. L., Long, M. A.-, Us, I. L., Morris, J. B., & Boyer, M. (2007). *United States Patent Cink et a]. SALTS OF FENOFIBRIC ACID AND (45) Date of Patent : 2*(12).

USP 32 – NF 27, 2009, United States Pharmacopeia and The National Formulary, Rockville (MD): The United States Pharmacopeial Convention.

Vogt, M., Kunath, K., & Dressman, J. B. (2008). Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. *European Journal of Pharmaceutics and Biopharmaceutics*, *68*(2), 283–288. https://doi.org/10.1016/j.ejpb.2007.05.010

Vogel, G. (2002) *D*rug Discovery and Evaluation Pharmacological Assays Second Edition, Human & Experimental Toxicology.

Wang, L., Tan, B., Zhang, H., & Deng, Z. (2013). Pharmaceutical cocrystals of diflunisal with nicotinamide or isonicotinamide. Organic Process Research and Development, 17(11), 1413–1418. https://doi.org/10.1021/op400182k

Wei, X., Li, P., Liu, M., Du, Y., Wang, M., Zhang, J., Wang, J., Liu, H., & Liu, X. (2017). Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. *Biomedical Chromatography*, *31*(4). https://doi.org/10.1002/bmc.3832

Weil, A., Caldwell, J. O. H. N., & Strolin-Benedetti, M. A. R. G. H. E. R. I. T. A. (1990). The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug metabolism and disposition, 18(1), 115-120.

Windriyati, Y. N., Sumirtapura, Y. C., & Pamudji, J. S. (2020). Comparative in vitro and in vivo evaluation of fenofibric acid as an antihyperlipidemic drug. *Turkish Journal of Pharmaceutical Sciences*,*17*(2),203–210

Yang, J., & Adams, J. (2005). NICotinamide and its Pharmacological Properties for CliNICal Therapy. *Drug Design Reviews-Online*, *1*(1), 43–52. https://doi.org/10.2174/1567269043480726

Yamashita, H., Hirakura, Y., Yuda, M., Teramura, T., & Terada, K. (2013). Detection of cocrystal formation based on binary phase diagrams using thermal analysis. Pharmaceutical Research, 30(1), 70–80. https://doi.org/10.1007/s11095-012-0850-1

Yousaf, A. M., Ramzan, M., Shahzad, Y., Mahmood, T., & Jamshaid, M. (2019). Fabrication and in vitro characterization of fenofibric acid-loaded hyaluroNIC acid–polyethylene glycol polymeric composites with enhanced drug solubility and dissolution rate. *International Journal of Polymeric Materials and Polymeric Biomaterials*, *68*(9), 510–515. https://doi.org/10.1080/00914037.2018.1466137

Yuliandra, Y., Zaini, E., Syofyan, S., Pratiwi, W., Putri, L. N., Pratiwi, Y. S., & Arifin, H. (2018). Cocrystal of ibuprofen–Nicotinamide: Solid-state characterization and in vivo analgesic activity evaluation. *Scientia Pharmaceutica*, *86*(2). https://doi.org/10.3390/scipharm86020023

Zaini, E., Halim, A., Soewandhi, S. N., & Dwi Setyawan. (2011). Peningkatan Laju Pelarutan Trimetoprim Melalui Metode Ko-Kristalisasi Dengan Nikotinamid. *Jurnal Farmasi Indonesia*, *5*(July), 206–212.

Zhou, W., Apkarian, R., Wang, Z. L., & Joy, D. (2007). Fundamentals of scanning electron microscopy (SEM). *Scanning Microscopy for Nanotechnology: Techniques and Applications*, 1–40. https://doi.org/10.1007/978-0-387-39620-0_1

Zhu, T., Ansquer, J. C., Kelly, M. T., Sleep, D. J., & Pradhan, R. S. (2010). Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. *Journal of Clinical Pharmacology*, *50*(8), 914–921. https://doi.org/10.1177/0091270009354995


UNIVERSITAS ANDALAS
UNTUK
KEDJAJAAN
BANGSA